#antimicrobialresistance

[ioag]

Pseudomonas aeruginosa is one of the most pleasant bacteria to identify from a microbiologist's perspective. In turn, from the veterinarian's point of view - one of the worst to treat.

[geohoneylovers]

🐝🔬 Honeybees, the tiny guardians of our health! 🌍✨ Fascinating research reveals how patrolling honey bees are exposing the threat of antimicrobial resistance. 🍯👩‍🔬 Dive into the buzz-worthy findings here: Click

[thehealthpulsek]

How Counterfeit Antibiotics Fuel Antimicrobial Resistance in Africa Drug-resistant infections in Africa are rising due to counterfeit antibiotics, causing over 1 million deaths annually and worsening AMR.... https://thehealthpulse.org/2026/06/11/how-counterfeit-antibiotics-fuel-amr-africa/

[inovineconferences]

𝟐𝐧𝐝 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐨𝐧 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 & 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝟐𝟎𝟐𝟔

𝐄𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐚 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐎𝐫𝐚𝐥 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧!

𝐖𝐞 𝐚𝐫𝐞 𝐝𝐞𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐭𝐨 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭 𝐃𝐚𝐦𝐚𝐥𝐢𝐞 𝐍𝐚𝐤𝐚𝐧𝐣𝐚𝐤𝐨 𝐚𝐬 𝐚 𝐬𝐩𝐞𝐚𝐤𝐞𝐫 𝐚𝐭 𝐭𝐡𝐞 𝟐𝐧𝐝 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐨𝐧 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 & 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝟐𝟎𝟐𝟔.

📅 Date: August 17–18, 2026 📍 Location: Orlando, Florida, USA

𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐓𝐢𝐭𝐥𝐞: Multidrug Resistant Klebsiella Pneumoniae and Escherichia Coli Were the Leading Causes of Death Among Patients Hospitalized at Mulago National Referral Hospital, Kampala, Uganda

This insightful research sheds light on the growing threat of antimicrobial resistance and its impact on patient outcomes—an area of critical importance in global healthcare.

Affiliation: Makerere University College of Health Sciences, Uganda Presentation Type: Oral Presentation

If you are interested in presenting your research, we warmly invite you to submit your abstract: 

Join us in welcoming her to share valuable knowledge and contribute to advancing infectious disease research worldwide.

[bondeichbook]

“This handbook provides a comprehensive, multidisciplinary examination of antimicrobial resistance, detailing molecular mechanisms, manifestations across microbial types, and the evolutionary and structural facets of resistance.” Handbook of Antimicrobial Resistance, 1st Edition, 2017

Handbook of Antimicrobial Resistance, 1st Edition (2017) is an authoritative and expansive reference designed for researchers, clinicians, microbiologists, pharmacologists, and public health professionals confronting the global crisis of antimicrobial resistance (AMR). Edited by leading experts Matthias Götte, Albert Berghuis, Greg Matlashewski, Mark Wainberg, and Donald Sheppard, this volume synthesizes cutting-edge scientific knowledge on how microbes become resistant to antimicrobial drugs across bacterial, viral, parasitic, and fungal pathogens. The book explains the molecular mechanisms of resistance, biochemical and structural aspects of drug-microbe interactions, and evolutionary pathways that drive resistance, and discusses strategies for combating AMR in clinical and research settings. Its comprehensive coverage makes it an essential tool for understanding, teaching, and researching antimicrobial resistance in a rapidly evolving public health landscape.

click the link below to get your copy now👇👇👇:

[rakshakulkarni]

Cefepime Market Development Accelerated by Rising Awareness of Antibiotic Resistance and Effective Treatments

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cefepime Market Size, Share & Trends Analysis Report By Type (Oral Formulations, Injectable, and Combination Therapies), Application (Pneumonia, Meningitis, Urinary Tract Infections, Bloodstream Infections, Skin and Soft Tissue Infections, and Intra-abdominal Infections), Distribution Channel (Hospital Pharmacies and Retail Pharmacies),-Market Outlook And Industry Analysis 2034"

Global Cefepime Market is valued at US$ 2.0 Bn in 2024 and it is expected to reach US$ 3.86 Bn by 2034, with a CAGR of 7.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3274

Cefepime, a fourth-generation cephalosporin antibiotic, is indicated for the management of a wide spectrum of serious bacterial infections. Its mechanism of action involves the inhibition of bacterial cell wall synthesis, resulting in the eradication of susceptible pathogens. Cefepime exhibits activity against both Gram-positive and Gram-negative bacteria, including strains resistant to earlier-generation cephalosporins. It is commonly utilized in the treatment of severe infections such as pneumonia, intra-abdominal infections, skin and soft tissue infections, urinary tract infections, and febrile neutropenia.

The global cefepime market is mature and largely consolidated, with generic manufacturers dominating due to the drug’s established presence in hospital formularies. The market is characterized by high-volume, price-sensitive competition among multiple players. Sustained demand is underpinned by cefepime’s continued inclusion in clinical treatment guidelines for critical bacterial infections and its strategic application within antimicrobial stewardship programs as a targeted therapeutic agent. The market is further defined by the predominance of injectable formulations, reflecting its critical role in hospital-based care for severe infections.

List of Prominent Players in the Cefepime Market:

Hetero Labs Limited

Dr. Reddy's Laboratories

Mylan Pharmaceuticals

Cipla Limited

Lupin Pharmaceuticals

Sandoz

Aurobindo Pharma

Teva Pharmaceuticals

Zydus Cadila

Sun Pharmaceutical Industries Ltd.

AbbVie Inc.

Novartis AG

Fresenius Kabi

Bayer AG

Eli Lilly and Company

Shanghai United Cell Biotechnology Co., Ltd.

WuXi AppTec

BioRidge Pharma

Hikma Pharmaceuticals PLC

Alkem Laboratories Ltd.

Read Overview Report- https://www.insightaceanalytic.com/report/cefepime-market/3274

Market Dynamics

Drivers:

The global cefepime market is primarily driven by the increasing prevalence of bacterial infections, particularly those caused by antibiotic-resistant strains. The rising incidence of hospital-acquired infections, especially among immunocompromised patients, further supports market growth. Expanding utilization of cefepime in emerging markets, alongside ongoing enhancements in healthcare infrastructure, is contributing to market development. Heightened awareness of antibiotic resistance risks has amplified demand for effective therapeutic options such as cefepime. Additionally, the aging global population, which is more vulnerable to infectious diseases, provides sustained growth opportunities for the market.

Challenges:

The cefepime market faces several constraints that may impede expansion. Strict regulatory requirements for drug approval can delay the introduction of new formulations. The emergence and proliferation of antibiotic-resistant bacteria threaten the drug’s clinical effectiveness, potentially limiting its usage. Furthermore, the high costs associated with antibiotic development and production restrict accessibility in low-income regions, which may constrain broader market growth.

Regional Trends:

In 2024, North America retained its leadership position in the cefepime market, supported by an advanced healthcare infrastructure, high incidence of bacterial infections, and a strong presence of pharmaceutical manufacturers. The region’s focus on infection control, healthcare innovation, and substantial investment in medical research and development underpins continued demand for cefepime and reinforces North America’s dominant market position.

The Asia-Pacific region is anticipated to register the highest growth rate over the forecast period. Factors such as rising population, increasing healthcare awareness, and improved access to medical services are driving strong demand for effective antibiotic therapies, positioning the region as a key growth market for cefepime globally.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3274

Recent Developments:

In January 2025, the global healthcare company Fresenius Kabi announced the launch of a new injectable formulation of cefepime, a critical broad-spectrum antibiotic. This launch was a strategic initiative to broaden the company's existing portfolio of ready-to-sterilize antibiotics, which are essential for hospital and clinical use.

Segmentation of Cefepime Market-

By Type-

Oral Formulations

Injectable

Combination Therapies

By Application -

Pneumonia

Meningitis

Urinary Tract Infections

Bloodstream Infections

Skin and Soft Tissue Infections

Intra-abdominal Infections

By Distribution Channel-

Hospital Pharmacies

Retail Pharmacies

By Region-

North America-

The US

Canada

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

South East Asia

Rest of Asia Pacific

Latin America-

Brazil

Argentina

Mexico

Rest of Latin America

 Middle East & Africa-

GCC Countries

South Africa

Rest of Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:

InsightAce Analytic Pvt. Ltd.

Visit: https://www.insightaceanalytic.com/

Tel : [phone]

Asia: [phone]

[email protected]

[phcnepal]

Nepal's National Action Plan on Antimicrobial Resistance (2024-2028): Combating the Silent Pandemic

In an era where superbugs threaten global health, Nepal is stepping up with its second National Action Plan (NAP) on Antimicrobial Resistance (AMR) for 2024-2028. Aligned with the World Health Organization’s (WHO) Global Action Plan, this multisectoral strategy addresses the rising tide of antibiotic-resistant infections that could push millions into poverty and derail Sustainable Development…

Nepal's National Action Plan on Antimicrobial Resistance (2024-2028): Combating the Silent Pandemic

[shivmehara]

Respiratory Tract Infection Treatment Market Size Was Valued at USD 40.20 Billion in 2023, and is Projected to Reach USD 68.09 Billion by 20

Respiratory Tract Infection Treatment Market Size Was Valued at USD 40.20 Billion in 2023, and is Projected to Reach USD 68.09 Billion by 2032, Growing at a CAGR of 6.03% From 2024-2032